RXRX Recursion Pharmaceuticals, Inc.
$4.05▲ +6.58%
Healthcare
Other
After hours
$4.04▼ -0.25%
Oct 27, 6:01 PM ET
Volume 22.10M
Avg Volume (10D) 26.53M
Key Metrics & Fundamentals
Market Cap
$2.42B
P/E Ratio
–
Div Yield
0.00%
52W Range
2.77 - 6.25
% vs 50 MA
9.72%
% vs 200 MA
14.55%
RSI-14
54.4
MACD Histogram
-0.0300
Beta (1Y vs SPY)
2.87
Free Cash Flow
-$107.91M
Gross Rev
$7.30M
Gross Profit
-$4.19M
EBITDA
-$112.53M
COGS
$11.49M
Operating Exp
$130.78M
Operating Income
-$134.97M
EBIT
-$134.97M
Pretax Income
-$131.01M
Net Income
-$131.01M
EPS (Diluted)
-0.25
Price & Volume History
Loading chart…
Recent News
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
Zacks · Oct 26, 2026 4:50 PM ET
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
GlobeNewswire · Oct 26, 2026 4:05 PM ET
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
Zacks · Oct 20, 2026 4:50 PM ET
Meta Stock Gets $24 Million Vote of Confidence From Cathie Wood
GuruFocus.com · Oct 19, 2026 3:49 PM ET
Has Recursion Pharmaceuticals (RXRX) Fallen Far Enough on Sales?
Simply Wall St. · Oct 18, 2026 11:16 PM ET
Why Recursion Pharmaceuticals Stock Is In Focus After Drug Data And Sanofi Milestone
Simply Wall St. · Oct 18, 2026 10:12 PM ET
Is Recursion Pharmaceuticals (RXRX) Undervalued Following Sanofi’s First Option Milestone?
Simply Wall St. · Oct 18, 2026 9:11 PM ET
Recursion Pharmaceuticals (RXRX) Stock Sees Modest Fair Value Lift After Analyst Target Revisions
Simply Wall St. · Oct 18, 2026 8:20 PM ET
Recursion Pharmaceuticals (RXRX) Reached A $10 Million Immunology Milestone
Simply Wall St. · Oct 18, 2026 7:18 PM ET
Iambic CEO on taking an AI drug company public
BioPharma Dive · Oct 16, 2026 12:10 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See RXRX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.